Amicus Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
Amicus Therapeutics (Nasdaq: FOLD) will have its President and CEO, Bradley Campbell, present at the 41st Annual J.P. Morgan Healthcare Conference on January 9, 2023, at 2:15 p.m. PT in San Francisco, CA. Investors can access a live audio webcast of the presentation via the company's website. Amicus Therapeutics focuses on developing innovative treatments for rare diseases, showcasing a commitment to high-quality medicine delivery for patients in need.
- None.
- None.
PHILADELPHIA, Jan. 03, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that Bradley Campbell, President and Chief Executive Officer, will present at the 41st Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Monday, January 9, 2023 at 2:15 p.m. PT.
A live audio webcast of the presentation can also be accessed via the investors section of the Amicus Therapeutics corporate website at https://ir.amicusrx.com/events-and-presentations.
About Amicus Therapeutics
Amicus Therapeutics (Nasdaq: FOLD) is a global, patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare diseases. With extraordinary patient focus, Amicus Therapeutics is committed to advancing and expanding a pipeline of cutting-edge, first- or best-in-class medicines for rare diseases. For more information please visit the company’s website at www.amicusrx.com, and follow on Twitter and LinkedIn.
CONTACT:
Investors:
Amicus Therapeutics
Andrew Faughnan
Executive Director, Investor Relations
afaughnan@amicusrx.com
(609) 662-3809
Media:
Amicus Therapeutics
Diana Moore
Head of Global Communications
dmoore@amicusrx.com
(609) 662-5079
FOLD–G
FAQ
What is the date and time of Amicus Therapeutics' presentation at the J.P. Morgan Healthcare Conference?
Who will represent Amicus Therapeutics at the J.P. Morgan Healthcare Conference?
Where can I watch the Amicus Therapeutics presentation live?
What is the focus of Amicus Therapeutics as a biotechnology company?